Department of Psychiatry, University of Pennsylvania, Philadelphia, USA.
Am J Alzheimers Dis Other Demen. 2011 Sep;26(6):443-9. doi: 10.1177/1533317511424892. Epub 2011 Oct 18.
Rivastigmine treatment is associated with significant improvements on the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog) in patients with mild-to-moderate Alzheimer's disease (AD) and Parkinson's disease dementia (PDD). Both AD and PDD are purported to have different profiles of cognitive impairment, which may respond differentially to rivastigmine treatment. This was a retrospective analysis of 3 randomized, double-blind, rivastigmine trial databases (Investigation of transDermal Exelon in ALzheimer's disease [IDEAL; AD], EXelon in PaRkinson's disEaSe dementia Study [EXPRESS; PDD], and Alzheimer's Disease with ENA 713 [ADENA; AD]). Factor analyses of the 11 baseline ADAS-cog items derived the same factors in the 2 diseases, that is, "memory" and "language". Rivastigmine-treated AD and PDD patients showed significant improvements (P < .0001 versus placebo) on both factors. For both AD and PDD, rivastigmine had a numerically greater effect on memory than language. Treatment effect sizes were numerically greater in PDD compared with AD. Rivastigmine treatment is associated with improvement in memory and language in AD and PDD. The numerically greater response in PDD is consistent with greater cholinergic deficits in this disease state.
卡巴拉汀治疗与轻度至中度阿尔茨海默病（AD）和帕金森病痴呆（PDD）患者的阿尔茨海默病评估量表（ADAS-cog）认知子量表的显著改善相关。AD 和 PDD 据称具有不同的认知障碍特征，这可能对卡巴拉汀治疗有不同的反应。这是对 3 项随机、双盲、卡巴拉汀试验数据库（EXelon 在 AD 中的经皮研究 [IDEAL；AD]、EXelon 在 PDD 中的研究 [EXPRESS；PDD]和伴有 ENA 713 的 AD [ADENA；AD]）的回顾性分析。11 项基线 ADAS-cog 项目的因子分析在这两种疾病中得出了相同的因子，即“记忆”和“语言”。卡巴拉汀治疗的 AD 和 PDD 患者在这两个因子上均显示出显著改善（P <.0001 与安慰剂相比）。对于 AD 和 PDD，卡巴拉汀对记忆的影响大于语言。与 AD 相比，PDD 的治疗效果大小在数值上更大。卡巴拉汀治疗与 AD 和 PDD 中的记忆和语言改善相关。在 PDD 中，这种反应在数值上更大，与这种疾病状态中更大的胆碱能缺陷一致。
